GENOFOCUS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,025 KRW | -1.11% |
|
-4.73% | +3.07% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 151,612 | 124,478 | 246,391 | 183,817 | 122,761 | 88,872 |
| Enterprise Value (EV) 1 | 147,995 | 130,347 | 265,610 | 217,103 | 159,850 | 121,349 |
| P/E ratio | -61.5 x | -21.3 x | -20 x | -26.9 x | -9.46 x | -29.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.2 x | 8.33 x | 13.1 x | 7.1 x | 4.42 x | 3.29 x |
| EV / Revenue | 12.8 x | 8.72 x | 14.2 x | 8.39 x | 5.75 x | 4.49 x |
| EV / EBITDA | 331 x | -139 x | -108 x | -2,274 x | -89.7 x | -25.2 x |
| EV / FCF | -18.4 x | -12.8 x | -31.2 x | -34.7 x | -21.6 x | -5.49 x |
| FCF Yield | -5.44% | -7.83% | -3.21% | -2.88% | -4.63% | -18.2% |
| Price to Book | 2.52 x | 2.39 x | 6.2 x | 5.21 x | 5.14 x | 4.03 x |
| Nbr of stocks (in thousands) | 21,536 | 21,838 | 22,399 | 22,499 | 22,525 | 22,758 |
| Reference price 2 | 7,040 | 5,700 | 11,000 | 8,170 | 5,450 | 3,905 |
| Announcement Date | 19-03-19 | 20-03-16 | 21-03-17 | 22-03-21 | 23-03-23 | 24-03-20 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 11,518 | 14,942 | 18,769 | 25,874 | 27,802 | 27,008 |
| EBITDA 1 | 447.2 | -936.1 | -2,457 | -95.46 | -1,782 | -4,824 |
| EBIT 1 | -1,282 | -2,946 | -4,698 | -3,834 | -6,224 | -9,464 |
| Operating Margin | -11.13% | -19.72% | -25.03% | -14.82% | -22.39% | -35.04% |
| Earnings before Tax (EBT) 1 | -2,391 | -5,220 | -12,127 | -14,402 | -11,336 | -786.5 |
| Net income 1 | -2,316 | -5,757 | -12,217 | -6,817 | -12,968 | -2,950 |
| Net margin | -20.11% | -38.53% | -65.09% | -26.35% | -46.64% | -10.92% |
| EPS 2 | -114.4 | -267.0 | -551.1 | -304.0 | -576.2 | -130.5 |
| Free Cash Flow 1 | -8,047 | -10,209 | -8,514 | -6,249 | -7,397 | -22,116 |
| FCF margin | -69.87% | -68.33% | -45.36% | -24.15% | -26.61% | -81.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-03-19 | 20-03-16 | 21-03-17 | 22-03-21 | 23-03-23 | 24-03-20 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 5,869 | 19,219 | 33,286 | 37,089 | 32,477 |
| Net Cash position 1 | 3,618 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -6.27 x | -7.822 x | -348.7 x | -20.81 x | -6.733 x |
| Free Cash Flow 1 | -8,047 | -10,209 | -8,514 | -6,249 | -7,397 | -22,116 |
| ROE (net income / shareholders' equity) | -3.81% | -9.39% | -24% | -20.4% | -37.7% | -2.34% |
| ROA (Net income/ Total Assets) | -1.14% | -2.29% | -2.89% | -2.07% | -3.08% | -5.1% |
| Assets 1 | 203,145 | 251,018 | 423,190 | 329,606 | 420,753 | 57,804 |
| Book Value Per Share 2 | 2,790 | 2,381 | 1,775 | 1,568 | 1,061 | 968.0 |
| Cash Flow per Share 2 | 129.0 | 598.0 | 685.0 | 273.0 | 489.0 | 1,006 |
| Capex 1 | 7,417 | 8,430 | 14,330 | 8,712 | 4,021 | 1,212 |
| Capex / Sales | 64.39% | 56.42% | 76.35% | 33.67% | 14.46% | 4.49% |
| Announcement Date | 19-03-19 | 20-03-16 | 21-03-17 | 22-03-21 | 23-03-23 | 24-03-20 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +3.07% | 68.77M | |
| +5.41% | 105B | |
| -3.11% | 64.71B | |
| +73.33% | 49.72B | |
| +17.24% | 38.6B | |
| +6.13% | 32.54B | |
| +12.77% | 19.94B | |
| +15.03% | 16.92B | |
| +19.06% | 15.2B | |
| +6.28% | 14.39B |
- Stock Market
- Equities
- A187420 Stock
- Financials GenoFocus, Inc.
